|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most active hybrid 7j (MIC: <0.016, 0.062 and 0.16 μg/mL, respectively) was >4.8 and ≥ 48 folds more potent than the first line anti-TB agents RIF and INH against both drug-sensitive MTB H<sub>37</sub>Rv and MDR-TB isolates, respectively.
|
30690301 |
2019 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
All Rifampicin resistant smear negative pulmonary TB isolates by Xpert MTB/ RIF assay were found to be MDR TB and 7/26 (26.9%) isolates were INH mono resistant.
|
31324227 |
2019 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of Xpert<sup>®</sup> MTB/RIF testing and GxAlert on MDR-TB diagnosis and linkage to care in Mozambique.
|
30355417 |
2018 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the 703 analysed strains, 12.8% were MDR; Ser531Leu and Ser315Thr being the most common recorded mutations within rpoB and katG genes associated with RIF and INH resistance respectively.
|
29486710 |
2018 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both of them were comparable to the first-line anti-TB agents INH and RIF against MTB H37Rv, and were far more potent than INH and RIF against MDR-TB 16833 and 16995 strains.
|
30119957 |
2018 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine whether the remnants of sputa prepared for the Xpert assay could be used directly to find mutations associated with drug resistance and to study molecular epidemiology, thus providing precise characterization of MDR-TB cases in countries lacking biosafety level 3 (BSL3) facilities for <i>M. tuberculosis</i> cultures.
|
28446574 |
2017 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
For best scale-up of MDR-TB diagnosis in Zimbabwe, GeneXpert-MTB/RIF can be used for rapid detection of TB in smear negative cases, RIF-susceptibility for early treatment initiation and probable MDR-TB.
|
31085822 |
2017 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hybridization of immobilized probes with the PCR products of TB and MDR-TB-RIF strains allow their detection and discrimination.
|
26999135 |
2016 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the 1222 Mtb isolates, 298 (24.4%) were resistant to 1st-line drug and 73 (5.9%) were simultaneously resistant to INH and RIF namely MDR-TB.
|
26980491 |
2016 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
MTB-DR-RIF 9G membrane: a platform for multiplex SNP detection of multidrug-resistant TB.
|
25967151 |
2015 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
RIF resistance was found in 6/213 (2.8%) cases, INH resistance was found in 3/215 (1.4%) cases, and MDR-TB was found in 8/223 (3.6%) cases.
|
22740709 |
2012 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
A susceptibility test demonstrated an MDR profile (INH(R), RIF(R), SM(R), and EMB(R), with the sputum isolate also exhibiting EMB(S) (R = resistant; S = sensitive).
|
19377792 |
2009 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two of the samples (4%) had mutations in genes associated to both INH and RIF and can be classified as MDR-TB.
|
12099732 |
2002 |